Large study reveals Real-World outcomes of immunotherapy in advanced kidney cancer
NCT ID NCT05858749
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study reviewed medical records of 494 adults with advanced kidney cancer who received immunotherapy as their first treatment. Researchers looked at how long patients stayed on treatment, how they responded, and survival rates. The goal was to understand which treatment combinations work best in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer Headquarters
New York, New York, 10017, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- Radiation boosts immunotherapy in kidney cancer trial
- Immunotherapy duo shows promise in kidney cancer battle
- Brain cancer trial halted early: can Memory-Sparing radiation help when tumors return?
- Folic acid may soothe cancer treatment side effects